Led · Series A · Jul 2026

TYBR Health develops extracellular matrix-based products intended to protect healing tissues following surgery, centered on its FDA-cleared B3 GEL® System. B3 GEL® is a flowable extracellular matrix hydrogel designed to conform to complex three-dimensional anatomy and be rapidly applied within existing surgical workflows. Since launch, the system has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures, with early adoption by surgeons seeking straightforward intraoperative tissue protection. The company says the product adheres where applied and forms a protective barrier through the healing window. TYBR Health plans to use the Series A proceeds to expand commercial access, broaden indications, and run clinical studies evaluating tissue protection during orthopedic surgery. The company is headquartered in Houston, Texas.

Participated · Equity · Oct 2025

Founded in 2014 by orthopedic surgeon Dr. Steven Goldberg, Catalyst OrthoScience develops shoulder arthroplasty solutions that emphasize bone preservation, soft-tissue protection, and reproducible results. Its flagship total-shoulder systems and the recently launched Catalyst Fracture Shoulder System aim to deliver a more natural-feeling joint while streamlining surgical workflow for physicians. The company’s technology portfolio includes a growing list of issued and pending patents, and its products are already available to surgeons across the United States. Catalyst’s mission is to simplify complex procedures without compromising clinical outcomes, a strategy that has driven expanding surgeon adoption and enthusiasm. Backed by a strong investor base and a leadership team with a record of disciplined growth, the firm plans to accelerate commercial and clinical programs and broaden its footprint in hospital and ambulatory surgery center markets. The new $15 million growth financing strengthens the balance sheet and provides capital for continued innovation and market expansion.

Led · Series A · Jul 2025

Cooler Heads develops Amma™, which the company describes as the only FDA‑cleared portable scalp cooling system, designed to help chemotherapy patients keep their hair and preserve privacy. Amma provides infusion centers and patients flexibility to scalp cool where it is most convenient, using a continuous cooling system that eliminates the need for dry ice or frequent cap changes. By cooling the scalp before, during, and after chemotherapy, Amma reduces blood flow to hair follicles to shield them from chemotherapy drugs and prevent hair loss. The company was founded by breast cancer survivor Kate Dilligan, who serves as CEO. Cooler Heads positions Amma as a low‑friction therapy for infusion centers and notes the American Medical Association’s decision to elevate scalp cooling reimbursement codes to Category I starting January 2026 as creating momentum. The business also offers evidence‑based products, content, and services to help patients manage treatment side effects. Cooler Heads develops Amma, an FDA-cleared scalp-cooling medical device intended to help cancer patients undergoing chemotherapy preserve their hair. The company positions its product as dramatically less expensive and easier to use than existing scalp-cooling solutions. Founder and CEO Kate Dilligan, a cancer survivor, built an early prototype herself and pursued clinical relationships before raising institutional capital. Cooler Heads announced FDA clearance and said it has signed multiple commercial partnerships and will begin serving patients in Q1 2022. The company highlighted its mission-driven focus on patient dignity and plans to push commercialization to make scalp cooling broadly accessible. Cooler Heads has been backed by several venture investors and industry leaders and has participated in accelerators and medtech competitions.

Participated · Series B · May 2025

Olio offers a secure software platform that enables real-time collaboration between acute and post-acute healthcare providers—including skilled nursing facilities, home health agencies, and outpatient physical therapy centers—so patient conditions are visible across the care continuum. By giving hospitals and physician teams immediate insight into post-discharge patient status, the solution aims to drive better clinical outcomes and lower overall costs. The company has already partnered with several Midwest health systems that participate in value-based reimbursement models such as Medicare Advantage, Managed Medicaid, BCPI-A, and ACO contracts. Management plans to use newly raised capital to scale the technology, expand nationally, and invest in engineering, marketing, and customer success. Future development will focus on deeper product innovation in collaboration with existing clients and onboarding additional health systems and post-acute providers. No revenue or user metrics were disclosed, but the company’s adoption within risk-bearing provider networks suggests growing traction.

Participated · Series B · Feb 2024

Redi Health operates a mobile and web platform that integrates health management technology with pharmaceutical manufacturer support to connect Pharma, Providers, and Patients on a single platform. The platform provides medication reminders, symptom management, educational resources, and real-time information exchange. Redi positions its product as a solution to high non-adherence rates (approximately 70%) that contribute to substantial industry losses. The company said it will use the new capital to foster innovation, develop and launch new products, further expand its patient network, and accelerate growth. Management framed the funding as a way to improve patient health outcomes and make comprehensive care accessible to millions across the country. Redi.Health is a Columbus, OH-based provider of a health management technology platform that helps patients with chronic conditions understand, manage, and track their total health. Its platform combines health management technology with pharmaceutical manufacturer support and includes a mobile app that lets patients manage multiple medications, symptoms, diet, and exercise. The company has signed partnerships with GoodRx and ScriptDrop and is collaborating with Labcorp to integrate Labcorp Drug Development Patient Access Solutions into its digital support platform. Led by CEO Luke Buchanan, Redi.Health plans to use growth funding to expand its business reach and accelerate product and patient-outcome advancements in 2023. The article reports the company secured growth funding of an undisclosed amount and does not disclose operating metrics or further financial details. Redi.Health builds a health management platform for polychronic patients, combining daily health-management tools, connections to pharmaceutical manufacturer support, and AI-driven health literacy. The product is designed to improve medication adherence and overall quality of life for patients with three or more chronic conditions. Redi.Health provides a single, patient-centric pathway for pharma companies, hubs, and specialty pharmacies to support and engage patients digitally. The company emphasizes simplified tools and novel connectivity to resources patients otherwise might not access. Founded in 2021 and based in Columbus, Ohio, Redi.Health plans to accelerate commercialization and broaden availability of its platform.